project-idea

PIES Score Calculator: Pancreatic Cancer Subtype from ctDNA Epigenomics

PIES (Pancreatic Integrated Epigenomic Score) can determine whether a patient's pancreatic cancer is classical or basal-like — predicting treatment response — from a blood draw, without biopsy.

Build an open-source implementation of the PIES scoring pipeline that takes cfDNA epigenomic profiling data as input (from standard liquid biopsy platforms) and outputs a PIES score with subtype classification and confidence interval. The tool would be designed to run in a standard bioinformatics environment (Nextflow or Snakemake pipeline) and output a clinical-grade report.

The pipeline would implement the published PIES methodology — integrating circulating histone modification and DNA methylation signals — with clear documentation of each step, QC thresholds, and interpretation guidelines. A companion web calculator for manual score entry (for clinicians reviewing published PIES values) would lower the barrier further.

Beyond the tool itself, the project could include a curated public dataset of PIES scores from the paper's multi-institutional cohort (if authors share data), enabling benchmark comparisons and validation by other labs. This is the kind of reference implementation that accelerates clinical translation — without it, PIES risks staying a research curiosity rather than becoming a clinical test.

Who Is This For?

Pancreatic cancer researchers, clinical molecular pathologists, bioinformaticians at cancer centers, and liquid biopsy platform developers.

Skills & Tools Needed

Bioinformatics pipeline development (Nextflow or Snakemake)
Epigenomics data processing (bismark for methylation, ChIP-seq/CUT&TAG for histone marks)
R or Python for score computation and statistical modeling
Clinical report generation (R Markdown, Quarto, or ReportLab)
Understanding of PDAC biology and subtype classification

Feasibility

medium — The methodology is published and the data types are standard, but epigenomics pipeline development requires specialized expertise and access to cfDNA epigenomic profiling data for validation.

Inspired by: Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.